Figure S1. Applied Biosystems GeneMapper Software 5 analysis of STR sequences of the PE8 cell line. Alleles of 13 STR sequences are shown.



Figure S2. Applied Biosystems GeneMapper Software 5 analysis of STR sequences of the PE8 cell line. Alleles of 3 STR sequences are shown, plus the last part of the idiogram to prove that the complete allelic analysis has been finished.



Figure S3. Applied Biosystems GeneMapper Software 5 analysis of STR sequences of the PE9 cell line. Alleles of 9 STR sequences are shown.



Figure S4. Applied Biosystems GeneMapper Software 5 analysis of STR sequences of the PE9 cell line. Alleles of 7 STR sequences are shown.



Figure S5. Applied Biosystems GeneMapper Software 5 analysis of STR sequences of the PE9 cell line. The last part of the idiogram is shown to prove that the complete allelic analysis has been finished.



Figure S6. CI indices expressed in logarithmic scale for the APR-246 and DZ-Nep treatment combination. When expressed in logarithmic terms, the figure reflects synergy for LogCI <0 and antagonism for LogCI >0. Each point corresponds to the average of three independent experiments. Fa axis reflects the affected fractions produced by the different combinations of drugs used at different concentrations. A72D72, double simultaneous treatment of APR-246 and DZ-Nep for 72 h; A24D48, pretreatment of APR-246 for 24 h followed by post-treatment with DZ-Nep for 48 h; D24A48, pretreatment of DZ-Nep for 24 h followed by post-treatment with APR-246 for 48 h; CI, Combinational Index; Fa, affected cellular fraction; DZ-Nep, 3-deazaneplanocin A.



Figure S7. CI indices expressed in logarithmic scale for the APR-246 and panobinostat treatment combination. When expressed in logarithmic terms, the figure reflects synergy for LogCI <0 and antagonism for LogCI >0. Each point corresponds to the average of three independent experiments. Fa axis reflects the affected fractions produced by the different combinations of drugs used at different concentrations. A72P72, double simultaneous treatment of APR-246 and panobinostat for 72 h; A24P48, pretreatment of APR-246 for 24 h followed by post-treatment with panobinostat for 48 h; P24A48, pretreatment of panobinostat for 24 h followed by post-treatment with APR-246 for 48 h; CI, Combinational Index; Fa, affected cellular fraction.



Figure S8. CI indices expressed in logarithmic scale for the APR-246 and temozolomide treatment combination. When expressed in logarithmic terms, the figure reflects synergy for LogCI <0 and antagonism for LogCI >0. Each point corresponds to the average of three independent experiments. Fa axis reflects the affected fractions produced by the different combinations of drugs used at different concentrations. A72T72, double simultaneous treatment of APR-246 and temozolomide for 72 h; A24T48, pre-treatment of APR-246 for 24 h followed by post-treatment with temozolomide for 48 h; T24A48, pretreatment of temozolomide for 24 h followed by post-treatment with APR-246 for 48 h; CI, Combinational Index; Fa, affected cellular fraction.



Figure S9. Triple simultaneous treatment of APR-246, panob and TMZ. CI indices expressed in logarithmic scale for the APR-246, panob and TMZ triple combination. When expressed in logarithmic terms, the figure reflects synergy for LogCI <0 and antagonism for LogCI >0. Each point corresponds to the average of three independent experiments. Fa axis reflects the affected fractions produced by the different combinations of drugs used at different concentrations. CI, Combinational Index; Fa, affected cellular fraction; Panob, panobinostat; TMZ, temozolomide.



Figure S10. Triple simultaneous treatment of APR-246, DZ-Nep and panob. CI indices expressed in logarithmic scale for the APR-246, DZ-Nep and panob triple combination. When expressed in logarithmic terms, the figure reflects synergy for LogCI <0 and antagonism for LogCI >0. Each point corresponds to the average of three independent experiments. Fa axis reflects the affected fractions produced by the different combinations of drugs used at different concentrations. CI, Combinational Index; Fa, affected cellular fraction; DZ-Nep, 3-deazaneplanocin A; Panob, panobinostat.



Figure S11. Triple simultaneous treatment of APR-246, DZ-Nep and TMZ. CI indices expressed in logarithmic scale for the APR-246, DZ-Nep and TMZ triple combination. When expressed in logarithmic terms, the figure reflects synergy for LogCI <0 and antagonism for LogCI >0. Each point corresponds to the average of three independent experiments. Fa axis reflects the affected fractions produced by the different combinations of drugs used at different concentrations. CI, Combinational Index; Fa, affected cellular fraction; DZ-Nep, 3-deazaneplanocin A; TMZ, temozolomide.



Figure S12. Clonogenic assay in soft agar with APR-246 and DZ-Nep. DZ-Nep, deazaneplanocin A.



Figure S13. Clonogenic assay in soft agar with APR and Panob. Panob, panobinostat; APR, APR-246.



